Researchers reported a new cancer-targeting strategy that combines bacterial tumor targeting, nutrient deprivation, and immune stimulation in a single engineered therapeutic. The approach uses a calreticulin-directed conjugate built from L-asparaginase linked to flagellin. In experiments using Salmonella-mediated tumor therapy, the L-asparaginase–flagellin construct showed improved antitumor activity, according to the study summary. The design aims to focus delivery toward calreticulin-bearing cancer cells while also invoking innate immune engagement via flagellin. The work suggests a multi-mechanism platform that could be adapted for tumor types with accessible calreticulin expression and for combination regimens where immune activation is desirable.